Titan Pharmaceuticals — Investor Presentation (January 2013)
21 slides from Titan Pharmaceuticals's investor presentation, Jan 7, 2013
Slide 1: Corporate Presentation January 2013
Exhibit 99.1 Corporate Presentation January 2013
Slide 2: Forward-looking statements
Thedescription the “projects,” currently production commercialization presentation anticipated or andsimilar of marketing may our and and terms, plans contain thesuch of uncertainty and variations the “forward-looking statements objectives Company’s of such patent involve fordrug future terms statem
Slide 3: Titan Pharmaceuticals Highlights
Specialty for continue treating Milestones: termthe value-creating treatment chronic topharmaceutical exist $165pain in of mil the opioid milestones Probuphine Royalties: market company dependence place Lean Tiered commercialization with Potential andSix double drug capital month development peak di
Slide 4: Prescription drug abuse crisis
Recognized that PRESCRIPTION Cabinet Opioid warrants Dependence—Viewed to Blame”, asimmediate an epidemic DRUG New and York ABUSE by significant Times as theanCRISIS, federal Epidemic (Sept resource government 23, Executive 2010) allocation ER Office “Prescription Visits NIDA of Due the(part Preside
Slide 5: Opioid Dependence: Disease Overview
Addiction significant death *American isproblems a primary, Society with chronic of one’s Addiction disease behaviors Medicine, of Addiction brain reward, Inc., involves 2011 motivation, Opioid cyclesDependence—Disease memory of relapse and and related remission neurobiological Overview Without trea
Slide 6: Opioid Dependence: Treatment Overview
In the U.S.safety Improved buprenorphine profile Lack hasof replaced euphoria methadone Ceiling Effect as theofgold Buprenorphine standard in treating Opioid Dependence—Treatment opioid dependence Buprenorphine Overviewis a mixed partial agonist at the mu receptor and an antagonist at the kappa rece
Slide 7: Opioid Dependence: Expanding Market
Daily outstripped in years CAGR brain rather buprenorphine for chemistry the those than lastmonths ofin 4 methadone years is addicts the Source: Source: current drives since EvaluatePharma; IMS gold greater 2006 Health standard share Implications Opioid Global ofReckitt patients Dependence—Expanding
Slide 8: Opioid Dependence: Concentrated Prescriber Base
Excellent margins Diversion, abuse Breakdown due to concentrated, of Suboxonetarget Prescribing prescriberPhysicians populationSource: 5,037 physicians IMS Healthwrote IM/FP/GP 90% of51% buprenorphine Psych 32% prescriptions Pain / Neuro 5% in 2010 Other Challenges 12% Opioid with Dependence—Concent
Slide 9: Probuphine: Long-Term Delivery
Solid Matrixand continuous Long-Term persistentDelivery around the Non-biodegradable clock blood levelsInserted of buprenorphine subdermally forStable 6 months non-fluctuating following a blood singlelevels treatment, of drug enhancing maintained patient for compliance over 6 months andProbuphine re
Slide 10: Probuphine implant composition
EVA polymer polymer Inert Buprenorphine component of several Blendedapproved & Extruded products 26 mmApproved long, 2.5 formm treatment diameter of Each opioidimplant addiction, contains and acute 80 mgand of chronic buprenorphine pain Probuphine HCl whichProbuphine has been blended and extruded wi
Slide 11: Probuphine Clinical Summary
Probuphine generally events level meeting, ofwas buprenorphine ifconsistent convened, low wasinclinically allwith studies iscontinuously anticipated the andand patient statistically similar in population forthe six tosecond superior placebo. months and half to and the The placebo ofknown isimplant M
Slide 12: Probuphine Target Patient Profile
Initial lifestyle Patients active market that have research Incarcerated high indicates relapse patients history that –physicians short Patients term with would It’streatment a way recommend to control compliance Probuphine incarceration-induced problems across New wide patients patient withdrawal P
Slide 13: Probuphine for Treatment of Chronic Pain
Buprenorphine transdermal implants 2003;349:1943-53 Probuphine patch has(3-7 Sittl, several value days) Expert advantages proposition is approved Rev. Neurotherapeutics over forintreating other U.S., Europe opioids chronic 2005;5(3): and used pain Australia for Around chronic 315-323 for thepain the
Slide 14: Intellectual Property
Patent applications Country AustraliaOpioid GrantedDependence (to are2023) for method-of-use Granted Pain Treatment (to 2023) claims U.S. New Method-of-use Granted Zealand(toGranted 2024) and Pending similar (to 2023) claims Europe Granted provide Pending (to 2023) strong Pending Hong protection Jap
Slide 15: Probuphine Value Proposition
Efficacy once distribution buprenorphine every Effective six (non-retail) monthsContinuous for six in reducing months, Probuphine illicit enhancing buprenorphine Value opioidpatient Proposition use Enhanced compliance delivery Probuphine compliance Non-fluctuating and retention is the mayfirst and l
Slide 16: Probuphine Commercial Partner: Braeburn
Probuphine potential Braeburn (acquired sciences businesses. milestone Pharmaceuticals, byCommercial Celgene), ofBraeburn $50 Heartware Partner million SprlPharmaceuticals Wholly-owned Exclusive International upon FDA commercialization approval is and bythe Apple Tokai first Tiered Tree division Pha
Slide 17: Braeburn Management and Resources
Probuphine Johnson level of Resources andJohnson & Commercial President, Well Senior Primary funded Partner Management—Key organization Care Experienced at Bristol with Team Myers personnel more Rose Squibb than Crane—Partner in commercial $75 Garry million Neil,allocated and at M.D.—Partner ATP ope
Slide 18: Titan: Adding Value Beyond Probuphine
Titan: drug clock Parkinson’s Evaluation Adding administration ofDisease additional Value (PD) Beyond compounds Established Stable Probuphine blood innon-clinical level other ProNeura of disease medication proof Technology settings of Sub-dermal concept underway Platform withdrug continuous Thedeliv
Slide 19: Financial Summary and Equity Position
Equity (Dec Position December (unaudited) 17,31, 2012 2012) Probuphine September Common30, licensing Stock 2012 Outstanding Cash agreement—upfront $ 5.1m 75.2 Debt m Stock $ 12.1m payment: Options/ Principal $15.75 Restricted $10m million +Stock Present Financial 6.8Value m Summary weighted-average
Slide 20: Goals for 2013
Goals the additional Parkinson’s U.S. forSeek 2013 indications disease regulatory Support establish and NDA approval Phase product review, IVand commitments development including commercialization possible Apply program advisory for partner Identify listingin committee the select additional Company’
Slide 21: Marc Rubin, M.D.
Marc Rubin, M.D. July 30, 2008
Titan Pharmaceuticals — Investor Presentation (January 2013) on 6ix